Lauxera HealthTech

The sector expertise of a HealthTech specialist combined with the experience of Pergam managers

The objective of the fund is to invest in the HealthTech sector to obtain a performance greater than MSCI World HealthCare

Investment Strategy

HealthTech brings together fast-growing companies in the medical sector that use new technologies to offer sustainable solutions for prevention and care, linking health care and innovation.

The complementarity of two experts: Lauxera, an expert company in the field of HealthTech, brings its in-depth knowledge of the sector. Pergam constructs the portfolio, optimises the investment timing and the weight of the positions

The investment process:
Extensive private equity due diligence. A concentrated portfolio of approximately 30 stocks.

Sustainable finance:
Lauxera HealthTech is an SFDR Article 8 fund

Lauxera HealthTech is a sub-fund of the Pergam Funds SICAV in compliance with the UCITS Directive.

97.55

VL €

( part IE )

105.73

VL $

( part IU )

AUM : 7.49 M€
02/02/2023
ISIN code euro share IE:
FR001400A6U8
ISIN code dollar unit IU:
FR001400A6W4
Legal form:
SICAV UCITS V under French law
Classification:
International Equities
Depositary:
ODDO BHF
Risk profile:
1 2 3 4 5 6 7
Recommended investment period:
7 ans
Valuation / Liquidity:
Daily
Management fees:
1.6% incl. tax for RE and RU shares / 1% incl. tax for IE and IU shares
Performance fee:
15% when annualised performance exceeds the MSCI World Health Care Net Total Return
Movement commission:
0%
Subscription/redemption fee:
2% max, not accruing to the fund for share subscriptions
None for redemptions
Countries authorised for marketing:
France

As the fund is less than one year old, the performance graph is not available.


First STOCKS lines in portfolio (as of 30/11/2022 )


Geographical distribution cash excluded (as of 30/11/2022 )

Performance is not constant over time and does not indicate future performance.

The sub-fund of the SICAV, which is incorporated under French law, is authorised for marketing in France. The risks and costs associated with investing in a UCITS are described in the Key Investor Information Document for this UCITS, which can be downloaded from this website. Pergam invites those concerned to take note of it. The Key Investor Information Document must be delivered to the subscriber prior to subscription. 

Our other
funds

Pergam Global Fund
Flexible and international management.

Pergam Active Dividend
Yield values in the European context.

Pergam Best Holdings
Investing in listed holding companies, managed by entrepreneurs and teams with a proven track record.

Software Conviction Fund
The sectorial expertise of a software specialist combined with the experience of Pergam's managers.

Amel HERRERA

Reception

Amel joined PERGAM in 2021 after 8 years of experience in the field of customer care.

Amel holds a BTS in accounting.

Welcome to the Pergam website

This site is an information site with the objective of presenting Pergam’s portfolio management activity as well as the main characteristics of its UCIs and services. It does not constitute a canvassing activity, an offer of securities or a public offering.

Access to the products and services presented on the site may be subject to restrictions with regard to certain persons, and in particular non-professional clients in accordance with the provisions of Article L.533 of the French Monetary and Financial Code and Directive 2004/39/EC on markets in financial instruments, or certain countries, and in particular with regard to investors in the United States who are subject to specific legislation. In addition, the products and services presented on this site may only be purchased in jurisdictions where they are authorised to be marketed and promoted.

If you are interested in any of the services or UCIs presented on this site, we advise you to ensure that you are legally entitled to subscribe to them. The information on the site is provided for information purposes only and does not release the user from undertaking additional and personalised analysis.

This site, and all the information presented on it, are governed by French law. Certain laws prohibit or restrict access to this site. We therefore ask you to ensure that you are legally entitled to connect to it in the country from which the connection is made.

To return to the home page of this site, click ‘Continue’.